Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Day One Biopharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Day One Biopharmaceuticals, Inc.’s stock price such as:

• Day One Biopharmaceuticals, Inc.’s current stock price and volume
• Why Day One Biopharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for DAWN from analysts
• DAWN’s stock price momentum as measured by its relative strength

About Day One Biopharmaceuticals, Inc. (DAWN)

Before we jump into Day One Biopharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Want to learn more about Day One Biopharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Day One Biopharmaceuticals, Inc..

Day One Biopharmaceuticals, Inc.’s Stock Price as of Market Close

As of March 10, 2026, 11:47 AM, CST, Day One Biopharmaceuticals, Inc.’s stock price was $21.375.

Day One Biopharmaceuticals, Inc. is up 0.21% from its previous closing price of $21.330.

During the last market session, Day One Biopharmaceuticals, Inc.’s stock traded between $21.280 and $21.430. Currently, there are approximately 103.65 million shares outstanding for Day One Biopharmaceuticals, Inc..

Day One Biopharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Day One Biopharmaceuticals, Inc. Stock Price History

Day One Biopharmaceuticals, Inc.’s (DAWN) price is currently up 101.65% so far this month.

During the month of March, Day One Biopharmaceuticals, Inc.’s stock price has reached a high of $21.430 and a low of $9.970.

Over the last year, Day One Biopharmaceuticals, Inc. has hit prices as high as $21.395 and as low as $5.635. Year to date, Day One Biopharmaceuticals, Inc.’s stock is up 129.35%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Day One Biopharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 09, 2026, there was 1 analyst who downgraded Day One Biopharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Day One Biopharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Day One Biopharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Day One Biopharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Day One Biopharmaceuticals, Inc. (DAWN) by visiting AAII Stock Evaluator.

Relative Price Strength of Day One Biopharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 09, 2026, Day One Biopharmaceuticals, Inc. has a weighted four-quarter relative price strength of 64.14%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Day One Biopharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Day One Biopharmaceuticals, Inc. Stock Price: Bottom Line

As of March 10, 2026, Day One Biopharmaceuticals, Inc.’s stock price is $21.375, which is up 0.21% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Day One Biopharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.